IR-Med, Inc. (IRME) Financial Ratio Screen
Track IRME screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
IRME financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2024. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: Not yet checked against an SEC annual filing.
Profile description reviewed: IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications. The company's development products pipeline consists of PressureSafe, a handheld skin-agnostic optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused by prolonged pressure on the sole of diabetic patients; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear, a common malady in children. IR-Med Inc. is headquartered in Rosh Pinna, Israel.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 62.5% / 30% | 51.4% / 30% | 72.9% / 30% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
| FTSE | 62.5% / 33% | 51.4% / 33% | 72.9% / 50% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -172.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$1M |
| Free Cash Flow | -$1M |
| Total Debt | $157,000 |
| Current Ratio | 0.1 |
| Total Assets | $251,000 |
Price & Trading
| Last Close | $0.01 |
| 50-Day MA | $0.00 |
| 200-Day MA | $0.03 |
| Avg Volume | 9K |
| Beta | 2.8 |
|
52-Week Range
$0.00
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-03-29 for the financial period December 2024. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About IR-Med, Inc. (IRME)
IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications. The company's development products pipeline consists of PressureSafe, a handheld skin-agnostic optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused by prolonged pressure on the sole of diabetic patients; and Nobiotics, an otoscope to support physicians with an immediate indication as to whether mid-ear, a common malady in children. IR-Med Inc. is headquartered in Rosh Pinna, Israel.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is IR-Med, Inc. (IRME) halal to invest in?
The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is IR-Med, Inc.'s debt ratio?
IR-Med, Inc.'s debt ratio is 62.5% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are IR-Med, Inc.'s key financial metrics?
IR-Med, Inc. has a market capitalization of USD 560,031 in its listing currency.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2024. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.